secwatch.observer — SEC 8-K summary
======================================

Issuer:     American Oncology Network, Inc. (—)
CIK:        0001839998
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001839998-24-000038
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

American Oncology Network Q1 revenue $364.3M (+20% YoY); net loss widens to $24.9M
--------------------------------------------------------------------------------

- Revenue $364.3M, up 20% YoY from $303.7M; patient encounters grew 7.1%.
- Net loss before non-controlling interest $24.9M vs $1.5M loss in Q1 2023.
- Adjusted EBITDA $2.0M, down from $4.1M in prior-year quarter.
- Added 17 new providers; expanded into Texas and Maryland markets.
- Cost of revenue up 27.4% driven by higher drug costs and $13.3M equity-based compensation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1839998/000183999824000038/0001839998-24-000038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1839998/000183999824000038/aonc-20240515.htm
  HTML page:      https://secwatch.observer/filing/0001839998-24-000038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer